Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2016 (2016), Article ID 7689862, 12 pages
http://dx.doi.org/10.1155/2016/7689862
Research Article

Different Strategies for the Treatment of Age-Related Macular Degeneration in China: An Economic Evaluation

1Medical Decision and Economic Group, Department of Pharmacy, Ren Ji Hospital, South Campus, School of Medicine, Shanghai Jiaotong University, Shanghai 201114, China
2Department of Ophthalmology, Ren Ji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200127, China
3Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai 200031, China
4Shanghai Key Laboratory of Visual Impairment and Restoration, Eye & ENT Hospital, Fudan University, Shanghai 200031, China

Received 7 December 2015; Revised 29 March 2016; Accepted 30 March 2016

Academic Editor: Biju B. Thomas

Copyright © 2016 Bin Wu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. S. Lim, P. Mitchell, J. M. Seddon, F. G. Holz, and T. Y. Wong, “Age-related macular degeneration,” The Lancet, vol. 379, no. 9827, pp. 1728–1738, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. W. Smith, J. Assink, R. Klein et al., “Risk factors for age-related macular degeneration: pooled findings from three continents,” Ophthalmology, vol. 108, no. 4, pp. 697–704, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Laude, P. D. Cackett, E. N. Vithana et al., “Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: same or different disease?” Progress in Retinal and Eye Research, vol. 29, no. 1, pp. 19–29, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. World Health Organization, Vision 2020, and International Agency for the Prevention of Blindness, Global Initiative for the Elimination of Avoidable Blindness: Action Plan 2006–2011, 2009, http://www.who.int/blindness/Vision2020%20-report.pdf.
  5. X. Li, Y. Hu, X. Sun, J. Zhang, and M. Zhang, “Bevacizumab for neovascular age-related macular degeneration in China,” Ophthalmology, vol. 119, no. 10, pp. 2087–2093, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. R. D. Jager, W. F. Mieler, and J. W. Miller, “Age-related macular degeneration,” The New England Journal of Medicine, vol. 358, no. 24, pp. 2606–2617, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. T. W. Olsen, X. Feng, T. J. Kasper, P. P. Rath, and E. R. Steuer, “Fluorescein angiographic lesion type frequency in neovascular age-related macular degeneration,” Ophthalmology, vol. 111, no. 2, pp. 250–255, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Zawinka, E. Ergun, and M. Stur, “Prevalence of patients presenting with neovascular age-related macular degeneration in an urban population,” Retina, vol. 25, no. 3, pp. 324–331, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. S. R. Earnshaw, Y. Moride, and S. Rochon, “Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada,” Clinical Therapeutics, vol. 29, no. 9, pp. 2096–2106, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Kondo, M. Asano, and H. Suzuki, “Significance of vascular endothelial growth factor/vascular permeability factor for solid tumor growth, and its inhibition by three antibody,” Biochemical and Biophysical Research Communications, vol. 194, no. 3, pp. 1234–1241, 1993. View at Publisher · View at Google Scholar · View at Scopus
  11. D. M. Brown, P. K. Kaiser, M. Michels et al., “Ranibizumab versus verteporfin for neovascular age-related macular degeneration,” The New England Journal of Medicine, vol. 355, no. 14, pp. 1432–1444, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. E. S. Gragoudas, A. P. Adamis, E. T. Cunningham Jr., M. Feinsod, and D. R. Guyer, “Pegaptanib for neovascular age-related macular degeneration,” The New England Journal of Medicine, vol. 351, no. 27, pp. 2805–2816, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. D. F. Martin, M. G. Maguire, G.-S. Ying, J. E. Grunwald, S. L. Fine, and G. J. Jaffe, “Ranibizumab and bevacizumab for neovascular age-related macular degeneration,” New England Journal of Medicine, vol. 364, no. 20, pp. 1897–1908, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. P. J. Rosenfeld, D. M. Brown, J. S. Heier et al., “Ranibizumab for neovascular age-related macular degeneration,” New England Journal of Medicine, vol. 355, no. 14, pp. 1419–1431, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Tufail, P. J. Patel, C. Egan et al., “Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study,” The British Medical Journal, vol. 340, Article ID c2459, 2010. View at Publisher · View at Google Scholar
  16. R. J. Casten, B. W. Rovner, and W. Tasman, “Age-related macular degeneration and depression: a review of recent research,” Current Opinion in Ophthalmology, vol. 15, no. 3, pp. 181–183, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. M. M. Brown, G. C. Brown, J. D. Stein, Z. Roth, J. Campanella, and G. R. Beauchamp, “Age-related macular degeneration: economic burden and value-based medicine analysis,” Canadian Journal of Ophthalmology, vol. 40, no. 3, pp. 277–287, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Cruess, G. Zlateva, X. Xu, and S. Rochon, “Burden of illness of neovascular age-related macular degeneration in Canada,” Canadian Journal of Ophthalmology, vol. 42, no. 6, pp. 836–843, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Bonastre, C. Le Pen, P. Anderson, A. Ganz, P. Berto, and G. Berdeaux, “The epidemiology, economics and quality of life burden of age-related macular degeneration in France, Germany, Italy and the United Kingdom,” The European Journal of Health Economics, vol. 3, no. 2, pp. 94–102, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. P. Mitchell, L. Annemans, R. White, M. Gallagher, and S. Thomas, “Cost effectiveness of treatments for wet age-related macular degeneration,” PharmacoEconomics, vol. 29, no. 2, pp. 107–131, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. C. Youxin, G. E. Jian, Y. A. N. Mi et al., “Clinical trial of verteporfin photodynamic therapy in Chinese age-related macular degeneration with subfoveal predominant choroidal neovascularization patients,” Chinese Journal of Ophthalmology, vol. 43, no. 3, pp. 198–205, 2007. View at Google Scholar
  22. W.-M. Chan, T. Y. Y. Lai, A. L. Wong, J.-P. Tong, D. T. L. Liu, and D. S. C. Lam, “Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularisation in age related macular degeneration: a comparative study,” British Journal of Ophthalmology, vol. 90, no. 3, pp. 337–341, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. World Development Indicators of China, October 2015, http://data.worldbank.org.cn/country/china.
  24. H.-G. Eichler, S. X. Kong, W. C. Gerth, P. Mavros, and B. Jönsson, “Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?” Value in Health, vol. 7, no. 5, pp. 518–528, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. C. J. L. Murray, D. B. Evans, A. Acharya, and R. M. P. M. Baltussen, “Development of WHO guidelines on generalized cost-effectiveness analysis,” Health Economics, vol. 9, no. 3, pp. 235–251, 2000. View at Google Scholar · View at Scopus
  26. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group, “Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials—TAP report,” Archives of Ophthalmology, vol. 117, no. 10, pp. 1329–1345, 1999. View at Publisher · View at Google Scholar
  27. N. M. Bressler, J. Arnold, M. Benchaboune et al., “Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report no. 3,” Archives of Ophthalmology, vol. 120, no. 11, pp. 1443–1454, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Arnold, I. Barbazetto, R. Birngruber et al., “Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials—TAP report 2,” Archives of Ophthalmology, vol. 119, no. 2, pp. 198–207, 2001. View at Google Scholar · View at Scopus
  29. Verteporfin in Photodynamic Therapy Study Group, “Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization—verteporfin in photodynamic therapy report 2,” American Journal of Ophthalmology, vol. 131, no. 5, pp. 541–560, 2001. View at Publisher · View at Google Scholar
  30. D. K. Miller and S. M. Homan, “Determining transition probabilities: confusion and suggestions,” Medical Decision Making, vol. 14, no. 1, pp. 52–58, 1994. View at Publisher · View at Google Scholar · View at Scopus
  31. “National Development and Reform Commission (NDRC),” July 2012, http://en.ndrc.gov.cn/.
  32. X. Zong, Y. Xie, S. M. Wu, L. Zhu, and L. H. Sun, “Economic analysis of verteporfin photodynamic therapy for the treatment of age-related macular degeneration,” China Journal of Pharmaceutical Economics, vol. 15, pp. 11–21, 2010. View at Google Scholar
  33. “Life tables for WHO Member States,” July 2015, http://www.who.int/gho/countries/chn/en/.
  34. J. C. Javitt, Z. Zhou, and R. J. Willke, “Association between vision loss and higher medical care costs in medicare beneficiaries costs are greater for those with progressive vision loss,” Ophthalmology, vol. 114, no. 2, pp. 238–245, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. R. Chen, Z. Hu, X. Qin, X. Xu, and J. R. M. Copeland, “A community-based study of depression in older people in Hefei, China-the GMS-AGECAT prevalence, case validation and socio-economic correlates,” International Journal of Geriatric Psychiatry, vol. 19, no. 5, pp. 407–413, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. J. T. Wang, Z. Chen, and Y. T. Song, “Falls in aged people of the Chinese mainland: epidemiology, risk factors and clinical strategies,” Ageing Research Reviews, vol. 9, pp. S13–S17, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. G. C. Brown, S. Sharma, M. M. Brown, and J. Kistler, “Utility values and age-related macular degeneration,” Archives of Ophthalmology, vol. 118, no. 1, pp. 47–51, 2000. View at Publisher · View at Google Scholar · View at Scopus
  38. J. J. Patel, M. A. S. Mendes, M. Bounthavong, M. L. D. Christopher, D. Boggie, and A. P. Morreale, “Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model,” Journal of Evaluation in Clinical Practice, vol. 18, no. 2, pp. 247–255, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. J. L. Colquitt, J. Jones, S. C. Tan, A. Takeda, A. J. Clegg, and A. Price, “Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation,” Health Technology Assessment, vol. 12, no. 16, pp. 3–201, 2008. View at Google Scholar
  40. K. Athanasakis, V. Fragoulakis, V. Tsiantou, P. Masaoutis, N. Maniadakis, and J. Kyriopoulos, “Cost-effectiveness analysis of ranibizumab versus verteporfin photodynamic therapy, pegaptanib sodium, and best supportive care for the treatment of age-related macular degeneration in Greece,” Clinical Therapeutics, vol. 34, no. 2, pp. 446–456, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. J. C. Javitt, G. P. Zlateva, S. R. Earnshaw et al., “Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity,” Value in Health, vol. 11, no. 4, pp. 563–574, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. G. Quellec, S. R. Russell, J. M. Seddon et al., “Automated discovery and quantification of image-based complex phenotypes: a twin study of drusen phenotypes in age-related macular degeneration,” Investigative Ophthalmology & Visual Science, vol. 52, no. 12, pp. 9195–9206, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. G. C. Brown, M. M. Brown, J. Campanella, and G. R. Beauchamp, “The cost-utility of photodynamic therapy in eyes with neovascular macular degeneration—a value-based reappraisal with 5-year data,” American Journal of Ophthalmology, vol. 140, no. 4, pp. 679.e1–679.e10, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. H.-B. Huang, Y. Pan, and T. Liu, “Shanghai eye treatment outbreak: bevacizumab therapy for AMD in China,” Clinical and Experimental Optometry, vol. 96, no. 1, pp. 106–108, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. X. Sun, X. Xu, and X. Zhang, “Counterfeit bevacizumab and endophthalmitis,” The New England Journal of Medicine, vol. 365, no. 4, pp. 378–379, 2011. View at Google Scholar · View at Scopus